News

AI giant, Nvidia (NASDAQ:NVDA), closed Tuesday’s session at $185.81, up 0.47%. Trading volume reached 158.40 million shares, coming in 16.51% below its three-month average of 184.56 million shares.

The S&P 500 (SNPINDEX:^GSPC) slipped 0.19% to 6,963.74 today even as December CPI data came in slightly lower than expected. The Nasdaq Composite (NASDAQINDEX:^IXIC) eased 0.10% to 23,709.87, and

Quantum computing is moving from the theoretical to the commercially applicable, but only one company has achieved 99.99% two-qubit gate fidelity (a measure of results accuracy). That company is

As economic uncertainty has grown, investors have increasingly turned to gold as an alternative to traditional investments in stocks, bonds, and other asset classes. Gold soared in 2025, and already

There is no hotter segment of the market right now than artificial intelligence (AI). AI stocks have powered the market higher over the past few years, and the technology still looks like it is in

The rise of artificial intelligence (AI) has ushered in a generational growth wave for companies all across the technology arena. In particular, semiconductor stocks have been some of the greatest

2025 was a great year for gold stocks, as prices of precious metals soared. Demand came from several quarters, including both the perception of gold as a store of value during troubled times and a

On Dec. 4, 2025, Freddy A. Jimenez, Senior Vice President & General Counsel of Celldex Therapeutics (NASDAQ:CLDX), executed an open-market sale of 4,166 insider shares. See SEC Form 4 filing.

Since 2018, Medicare Advantage Plans have had flexibility in what they cover, as the Bipartisan Budget Act of 2018 allowed plans to expand coverage to include Special Supplemental Benefits for the

On Jan. 5, John M. Leonard, the president and CEO of Intellia Therapeutics (NASDAQ:NTLA), executed an open-market sale of 34,146 directly held shares, totaling $314,484.66, as disclosed in a SEC

On Dec. 23, AnaptysBio (NASDAQ:ANAB) Director J. Anthony Ware executed an open-market sale of 3,900 shares for a transaction value of $193,342.50, representing 28.82% of his direct holdings

On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (NASDAQ:CORT), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately

Over the long run, the stock market has been the top performer among investment asset classes. Bonds, commodities, foreign currencies, real estate, and other assets have had their moments in the

Paul F. Lizzul, the chief medical officer of AnaptysBio (NASDAQ:ANAB), reported the direct sale of 3,650 shares of the company for a total consideration of approximately $163,191.50 on Thursday, as

Greg Zante, the chief financial officer of Viking Therapeutics (NASDAQ:VKTX), reported the direct sale of 57,661 shares of the biotech in multiple open-market transactions valued at $1.9 million

Dividend investing isn't inherently superior to other styles, as each has its own aims and goals. However, there is something to be said about dividend stocks: Over the long run, they outperform

Medicare Advantage plans are an alternative to traditional Medicare that can provide coverage for more services. The Bipartisan Budget Act of 2018 allowed Advantage Plans to cover things that were

Water is a precious resource that's essential for life. Since the early 1900s, Badger Meter (NYSE: BMI) has been involved in helping utilities and their customers monitor and manage their water use

More often than not, takeover speculation can give a lively boost -- at least in the short term -- to a company's stock. That was the dynamic behind the nearly 11% price gain of Revolution Medicines

The technology sector is an excellent place to find high-growth stocks with promising prospects. However, it is a cyclical sector that doesn't perform as well when the economy tanks. It's critical

The increasing demand for all things artificial intelligence (AI) helped Nvidia emerge out of nowhere to become the world's largest company as measured by market cap. Between the $4.6 trillion

Pfizer's (NYSE: PFE) shares have been southbound for the last three years. And unfortunately for the company, it doesn't look like things will improve significantly in 2026. The pharmaceutical

Capricor Therapeutics (NASDAQ: CAPR) stock rose an incredible 439.4% in December, according to data provided by S&P Global Market Intelligence. The move followed the company's announcement of